Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 226
Ph III recruiting: 25
Growth YoY: +3.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04681248	Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors	no longer available	—	—	Leap Therapeutics, Inc.INDUSTRY	1	Aug 3, 2025	clinicaltrials
NCT03493165	Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)	no longer available	—	—	The University of Texas Health Science Center at San AntonioOTHER	0	May 28, 2025